Partnership opportunities & commercial models
Whether you're a pharmaceutical company looking to license a delivery platform or a hospital network seeking clinical validation, there's a defined model to engage with Miragen.
Built for both ends of the pipeline
Co-development & technology licensing
- Co-development programs — formulate existing oncology assets into BBB-penetrating nanotubes or injectable wafers
- Combination therapies — develop synergistic regimens combining nanotherapeutics with standard-of-care agents
- Technology transfer — full GMP scale-up transfer of lipid nanoparticle or polymer platforms
Clinical validation & trials
- Clinical validation (SPR) — access to patient cohorts for validating biosensor sensitivity in breast and brain cancer
- Post-surgical trials — collaboration with neurosurgery departments for injectable wafer efficacy studies
- Early screening programs — deploy portable diagnostics for high-risk population screening initiatives
Five ways to structure a partnership
Indicative figures shown — final scope and pricing are agreed per project based on technology, territory, and exclusivity.
R&D Advisory
Prototype Dev
Scale-Up Services
Tech Transfer
Patent Licensing
A defined route to market on both platforms
The SPR biosensor follows the CDSCO Class C (IVD) pathway under the Medical Devices Rules, 2017, with an estimated 18–24 months to market authorization. Nanotherapeutic platforms follow the New Drug pathway under NDCT Rules 2019, targeting accelerated approval routes, with an estimated 5–7 years to NDA.
Manufacturing follows Schedule M (GMP) and ISO 13485 standards, with adaptive trial designs and Orphan Drug Designation being pursued to reduce the GBM clinical timeline.
A three-step path to working together
01 · Review Data
Examine our preclinical dossiers and patent claims.
02 · Define Model
Select co-development, clinical trial, or licensing.
03 · Execute Pilot
Initiate a prototype study or validation trial.
Why partner with Miragen
Proven Science
10+ peer-reviewed publications validating BBB penetration and tumor suppression, with successful proof-of-concept in orthotopic models.
Strong IP Portfolio
2 granted Indian patents covering injectable wafers (No. 408307) and dermal delivery (No. 366070) form a robust defensive moat.
Clinical Alignment
Directly addresses critical unmet needs in GBM survival (<7%) and affordable early cancer detection in India.
Scalable Platforms
Versatile technologies spanning diagnostics, therapeutics, and cosmeceuticals create multiple revenue streams.